FR2184934B1 - - Google Patents

Info

Publication number
FR2184934B1
FR2184934B1 FR7317756A FR7317756A FR2184934B1 FR 2184934 B1 FR2184934 B1 FR 2184934B1 FR 7317756 A FR7317756 A FR 7317756A FR 7317756 A FR7317756 A FR 7317756A FR 2184934 B1 FR2184934 B1 FR 2184934B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7317756A
Other versions
FR2184934A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AH Robins Co Inc
Original Assignee
AH Robins Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AH Robins Co Inc filed Critical AH Robins Co Inc
Publication of FR2184934A1 publication Critical patent/FR2184934A1/fr
Application granted granted Critical
Publication of FR2184934B1 publication Critical patent/FR2184934B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR7317756A 1975-08-13 1973-05-16 Expired FR2184934B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/604,371 US4045576A (en) 1975-08-13 1975-08-13 Anti-inflammatory methods using 2-amino-3-(5- and 6-)benzoylphenylacetic acids, esters and metal salts thereof and the compounds

Publications (2)

Publication Number Publication Date
FR2184934A1 FR2184934A1 (fr) 1973-12-28
FR2184934B1 true FR2184934B1 (fr) 1976-11-05

Family

ID=24419335

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7317756A Expired FR2184934B1 (fr) 1975-08-13 1973-05-16

Country Status (15)

Country Link
US (3) US4045576A (fr)
JP (3) JPS523381B2 (fr)
AT (2) AT329542B (fr)
AU (1) AU530940B2 (fr)
BE (2) BE799611A (fr)
CA (2) CA1012979A (fr)
CH (1) CH577461A5 (fr)
DE (2) DE2324768C2 (fr)
ES (1) ES446625A1 (fr)
FR (1) FR2184934B1 (fr)
GB (2) GB1432576A (fr)
MX (1) MX4035E (fr)
NL (1) NL183722C (fr)
PH (2) PH12656A (fr)
SE (1) SE400966B (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE400966B (sv) * 1975-08-13 1978-04-17 Robins Co Inc A H Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror
FR2366015A1 (fr) * 1975-11-05 1978-04-28 Robins Co Inc A H Nouveaux acides amino-2 benzoyl-3 (5 et 6) phenylacetiques et leurs esters et sels de metaux alcalins, utiles notamment comme anti-inflammatoires, et leur procede de preparation
US4221716A (en) * 1979-02-16 1980-09-09 A. H. Robins Company, Inc. Intermediate and process for the preparation of 7-acylindolin-2-ones
EP0089426B1 (fr) * 1979-07-12 1986-06-11 A.H. Robins Company, Incorporated Acides 2-amino-6-biphénylacétiques
IL60444A (en) * 1979-08-01 1985-03-31 Robins Co Inc A H 2-amino-3-(alkylthiobenzoyl)-phenylacetic acid derivatives and pharmaceutical compositions containing them
US4313949A (en) * 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
ZA805476B (en) * 1979-09-26 1981-11-25 Robins Co Inc A H 2-amino-3-benzoyl-phenylacetamides and cyclic homologues
US4254146A (en) * 1979-10-18 1981-03-03 A. H. Robins Company, Inc. 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters
IL61945A (en) * 1980-02-19 1984-09-30 Robins Co Inc A H 2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them
US4503073A (en) * 1981-01-07 1985-03-05 A. H. Robins Company, Incorporated 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids
IL64724A0 (en) * 1981-02-17 1982-03-31 Robins Co Inc A H 2-amino-3-(halobenzoyl)-methylphenylacetic acids and esters and salts thereof and pharmaceutical compositions containing them
JPS6019753A (ja) * 1983-07-13 1985-01-31 Shionogi & Co Ltd オルト−（モノ置換アミノ）フエニルイミン類およびその製造法
JPS6026586U (ja) * 1983-07-29 1985-02-22 日本軽金属株式会社 改装サッシ窓における隙間閉塞装置
SE8400239D0 (sv) * 1984-01-19 1984-01-19 Pharmacia Ab Nya arylettiksyraderivat
US4683242A (en) * 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
US4782089A (en) * 1986-08-26 1988-11-01 A. H. Robins Company, Incorporated 2-amino-3-aroyl-gamma-oxobenzenebutanoic acids and esters
US4880788A (en) * 1987-10-30 1989-11-14 Baylor College Of Medicine Method for preventing and treating thrombosis
CA1325382C (fr) * 1988-01-27 1993-12-21 Takahiro Ogawa Composition therapeutique a administration locale pour les affections inflammatoires
US5179119A (en) * 1989-08-02 1993-01-12 Hoechst-Roussel Pharmaceuticals Incorporated 1,3-dihydro-1-(pyridinylamino)-2H-indol-1-ones and intermediates for the preparation thereof
AU659106B2 (en) * 1990-11-06 1995-05-11 Fgn, Inc. Method for treating colonic polyps by the use of esters and amides of substituted phenyl and pyridyl amino carboxylates
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
KR20010012131A (ko) * 1997-04-28 2001-02-15 가부시키가이샤 이가쿠죠호서비스 케토프로펜 및 5-벤조일-3-메틸-2-인돌리논의 제조방법
AR030345A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes relacionados con angiogenesis
AR030346A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
JP2004529110A (ja) * 2001-03-06 2004-09-24 アストラゼネカ アクチボラグ 脈管損傷活性を有するインドール誘導体
WO2002078681A2 (fr) 2001-04-02 2002-10-10 Alcon, Inc. Procede permettant de traiter les troubles inflammatoires oculaires et les troubles lies a l'angiogenese du segment posterieur de l'oeil a l'aide d'un derive amide de flurbiprofen ou de ketorolac
US6692772B2 (en) * 2001-07-18 2004-02-17 Cedars-Sinai Medical Center Prevention of in-stent thrombosis and complications after arterial angioplasty with stent placement using magnesium
BR0309747A (pt) * 2002-05-03 2005-04-26 Alcon Inc Método para o tratamento de distúrbios vasculares mediados pelo fator de crescimento vascular endotelial
EP1586316B1 (fr) 2003-01-21 2008-04-30 Senju Pharmaceutical Co., Ltd. Preparation liquide aqueuse contenant de l'acide 2-amino-3-(4-bromobenzoyle) phenylacetique
US20030187072A1 (en) * 2003-02-14 2003-10-02 Kapin Michael A. Method of treating angiogenesis-related disorders
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
MY145694A (en) * 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
TW200812575A (en) * 2006-04-28 2008-03-16 Alcon Inc Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye
US20110237567A9 (en) * 2006-10-12 2011-09-29 Xenon Pharmaceuticals Inc. Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
EP2073806B1 (fr) * 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Utilisation de composés de spiro-oxindole comme agents thérapeutiques
US20110294842A9 (en) * 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
WO2008046083A2 (fr) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Utilisation de composés oxindole comme agents thérapeutiques
US20080153818A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for preventing inflammation during surgery
US20080153819A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
US20090105245A1 (en) * 2006-12-21 2009-04-23 Bingaman David P Methods for treating macular edema and ocular angiogenesis using an anti-inflammatory agent and a receptor tyrosine kinase inhibitor
US20090076150A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched bromfenac
JP2011513229A (ja) * 2008-02-21 2011-04-28 イスタ・ファーマスーティカルズ・インコーポレイテッド 補助剤としての眼科用ｎｓａｉｄ
EP2350091B1 (fr) * 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Composés spiro-oxindole et leur utilisation comme agents thérapeutiques
CN106928247A (zh) 2008-10-17 2017-07-07 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
PE20170202A1 (es) * 2009-10-14 2017-03-24 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol
GB2484843A (en) * 2009-10-15 2012-04-25 Johnson Matthey Plc Polymorphs of Bromfenac sodium
GB0919757D0 (en) 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US8299295B2 (en) 2009-10-15 2012-10-30 Johnson Matthey Public Limited Company Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
MA34083B1 (fr) 2010-02-26 2013-03-05 Xenon Pharmaceuticals Inc Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques
EP2377850A1 (fr) * 2010-03-30 2011-10-19 Pharmeste S.r.l. Antagonistes de récepteur vanilloïde TRPV1 avec portion bicyclique
TWI531566B (zh) * 2010-12-21 2016-05-01 拜耳農業科學股份有限公司 製備２－（三羰基）磺醯替苯胺類的方法
US20140142182A1 (en) 2012-11-19 2014-05-22 Bausch & Lomb Incorporated Aqueous Liquid Composition Containing 2-Amino-3-(4-Bromobenzoyl)Phenylacetic Acid
EA201591910A1 (ru) 2013-06-19 2016-05-31 Сентисс Рисерч Центр Стабильный раствор бромфенака
US20170000889A1 (en) 2013-12-12 2017-01-05 Sentiss Pharma Private Limited Stable bromfenac ophthalmic solution
CN104974057B (zh) * 2014-04-08 2018-05-18 天津金耀集团有限公司 一种溴芬酸钠的制备方法和重要中间体
CN104151182B (zh) * 2014-06-16 2016-03-30 广东众生药业股份有限公司 一种溴芬酸钠倍半水合物的制备方法
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
CN104693019B (zh) * 2015-02-06 2017-02-01 宁波九胜创新医药科技有限公司 一种2,5‑二溴苯乙酸的制备方法
CN106278917B (zh) * 2016-08-12 2018-05-08 合肥久诺医药科技有限公司 一种溴芬酸钠降解杂质标准品的合成方法
CN106278918B (zh) * 2016-08-12 2018-05-11 合肥久诺医药科技有限公司 一种溴芬酸钠杂质标准品2-氨基-3-(4-溴苯甲酰基)苯甲酸的合成方法
US11174327B2 (en) 2017-06-30 2021-11-16 Kuraray Co., Ltd. Method for producing modified polyvinyl alcohol resin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1226344A (fr) * 1967-07-31 1971-03-24
US3899529A (en) * 1973-02-22 1975-08-12 Merck & Co Inc Aroyl substituted naphthalene acetic acids
SE400966B (sv) * 1975-08-13 1978-04-17 Robins Co Inc A H Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror

Also Published As

Publication number Publication date
BE799611A (fr) 1973-09-17
JPS55349A (en) 1980-01-05
MX4035E (es) 1981-11-18
ES446625A1 (es) 1977-06-01
JPS5223052A (en) 1977-02-21
AT329542B (de) 1976-05-10
ATA977475A (de) 1978-05-15
SE400966B (sv) 1978-04-17
NL183722C (nl) 1989-01-02
CA1012979A (en) 1977-06-28
JPS5726585B2 (fr) 1982-06-05
DE2636582A1 (de) 1977-02-24
JPS523381B2 (fr) 1977-01-27
BE837154A (fr) 1976-04-16
CH577461A5 (fr) 1976-07-15
AU530940B2 (en) 1983-08-04
CA1087205A (fr) 1980-10-07
NL7306833A (fr) 1973-11-20
PH15112A (en) 1982-08-10
ATA429873A (de) 1975-08-15
US4126635A (en) 1978-11-21
DE2324768A1 (de) 1973-11-29
GB1521097A (en) 1978-08-09
DE2636582C2 (de) 1986-03-27
US4182774A (en) 1980-01-08
US4045576A (en) 1977-08-30
DE2324768C2 (de) 1985-08-14
PH12656A (en) 1979-07-11
FR2184934A1 (fr) 1973-12-28
AT347433B (de) 1978-12-27
NL183722B (nl) 1988-08-01
GB1432576A (en) 1976-04-22
AU6181480A (en) 1981-01-08
AU5584673A (en) 1974-11-21
JPS4941349A (fr) 1974-04-18

Similar Documents

Publication Publication Date Title
AR201758A1 (fr)
AU476761B2 (fr)
AU465372B2 (fr)
FR2184934B1 (fr)
AR201235Q (fr)
AR201231Q (fr)
AU474593B2 (fr)
AU474511B2 (fr)
AU474838B2 (fr)
AU471343B2 (fr)
AU465453B2 (fr)
AU465434B2 (fr)
AU450229B2 (fr)
AU476714B2 (fr)
AR201229Q (fr)
AU466283B2 (fr)
AU472848B2 (fr)
AU476696B2 (fr)
AR199451A1 (fr)
AU477823B2 (fr)
AR195948A1 (fr)
AU477824B2 (fr)
AR195311A1 (fr)
AR200885A1 (fr)
AR200256A1 (fr)

Legal Events

Date Code Title Description
TP Transmission of property